Axsome Therapeutics Inc (NASDAQ:AXSM) — Market Cap & Net Worth
Market Cap & Net Worth: Axsome Therapeutics Inc (AXSM)
Axsome Therapeutics Inc (NASDAQ:AXSM) has a market capitalization of $10.69 Billion ($10.69 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2126 globally and #792 in its home market, demonstrating a -1.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Axsome Therapeutics Inc's stock price $204.07 by its total outstanding shares 52380818 (52.38 Million). Also see Axsome Therapeutics Inc total assets for a full breakdown of the balance sheet.
Axsome Therapeutics Inc Market Cap History: 2015 to 2026
Axsome Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $485.57 Million to $10.69 Billion (33.76% CAGR). Also see Axsome Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Axsome Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.40% | #40 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.03% | #238 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.57% | #30 of 263 |
Weight: Axsome Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Axsome Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Axsome Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AXSM share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
14.98x
Axsome Therapeutics Inc's market cap is 14.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.98 Billion | $8.82 Million | -$134.94 Million | 224.38x | N/A |
| 2022 | $4.04 Billion | $50.04 Million | -$187.13 Million | 80.74x | N/A |
| 2023 | $4.17 Billion | $270.60 Million | -$239.24 Million | 15.41x | N/A |
| 2024 | $4.43 Billion | $385.69 Million | -$287.22 Million | 11.49x | N/A |
| 2025 | $9.57 Billion | $638.50 Million | -$183.17 Million | 14.98x | N/A |
Competitor Companies of AXSM by Market Capitalization
Companies near Axsome Therapeutics Inc in the global market cap rankings as of September 16, 2026. Review AXSM goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Axsome Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Axsome Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Axsome Therapeutics Inc's market cap moved from $485.57 Million to $ 10.69 Billion, with a yearly change of 33.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.69 Billion | +11.73% |
| 2025 | $9.57 Billion | +115.86% |
| 2024 | $4.43 Billion | +6.31% |
| 2023 | $4.17 Billion | +3.19% |
| 2022 | $4.04 Billion | +104.16% |
| 2021 | $1.98 Billion | -53.63% |
| 2020 | $4.27 Billion | -21.18% |
| 2019 | $5.41 Billion | +3565.25% |
| 2018 | $147.71 Million | -49.64% |
| 2017 | $293.33 Million | -17.04% |
| 2016 | $353.57 Million | -27.18% |
| 2015 | $485.57 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Axsome Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.69 Billion USD |
| MoneyControl | $10.69 Billion USD |
| MarketWatch | $10.69 Billion USD |
| marketcap.company | $10.69 Billion USD |
| Reuters | $10.69 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more